Even though anti-cancer agents targeting pyrimidine de novo synthesis via DHODH inhibition failed to prove their effectiveness in clinical trials, with advancing technologies and methodologies such as gene expression profiling and metabolomics, the importance of DHODH as a target in cancer was rediscovered. The gene discussed is DHODH; the disease is cancer.